Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression

Authors :: David I. Quinn
Daniel P. Petrylak
Joaquim Bellmunt
K. Nakajima
A. Holynskyj
Cora N. Sternberg
Hiroyuki Nishiyama
C. Lu
Source :: Annals of Oncology. 29:viii331
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: 0301 basic medicine
Chemotherapy
Metastatic Urothelial Carcinoma
business.industry
Fibroblast growth factor receptor 1
medicine.medical_treatment
Mrna expression
Locally advanced
Hematology
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
Cancer research
medicine
In patient
business

Full Text Access

Tools